Use of a multi‐electrode radiofrequency balloon catheter to achieve pulmonary vein isolation in patients with paroxysmal atrial fibrillation: 12‐Month outcomes of the RADIANCE study

• DOI: 10.1111/jce.14476
• Publication Date: 2020-04-06T13:23:38Z
• Authors: Gurpreet Singh Dh...; Shohreh Honarbakhsh; Antonio Di Monaco; Ann Elizabeth Coling; Kernerová Lenka; Francesca Pizzami...; Ross J. Hunter; Rodney Horton; Moussa Mansour; Andrea Natale; Vivek Reddy; Massimo Grimaldi; Petr Neuzil; Claudio Tondo; Richard J. Schilling
• Keywords: Paroxysmal atrial fibrillation; Isolation

The RADIANCE first-in-man study evaluated acute (3-month) safety and design concept in terms of utility a new multi-electrode radiofrequency (RF) balloon catheter (HELIOSTAR, Biosense Webster) to achieve pulmonary vein isolation (PVI). After conclusion, subset patients was followed up 12 months.Patients with drug refractory paroxysmal atrial fibrillation were enrolled. Neurological assessment, cardiac cerebral magnetic resonance imagings performed pre post procedure. Ablation delivered at 15 Watts each PV for 60 seconds (electrodes adjacent the posterior wall limited 20 seconds). Adenosine or isoproterenol administered confirm PVI. Esophageal endoscopy 48 hours Patients clinically months.Thirty-nine underwent ablation from four centers. Mean age 60.7 ± 10.0 years 23 (57.5%) being male. Confirmation PVI all PVs treated (152/152). after one delivery solely on 137 152 which 79.6% (109/137) achieved single RF energy. Acute reconnection seen 4.6% (7/150) PVs. Freedom documented arrhythmia months those 86.4% (32/37). A total 75.7% (28/37) free off antiarrhythmic medications.The HELIOSTAR allows rapid safe majority only requiring application.